Related Experiment Videos

Carvedilol: just another Beta-blocker or a powerful cardioprotector?

R S Carreira1, P Monteiro, L M Gon Alves

  • 1Basic Research Unit in Cardiology, Cardiology Department, Coimbra University Hospital, Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal.

Cardiovascular & Hematological Disorders Drug Targets
|March 24, 2007
PubMed

Insights

Carvedilol, a unique beta-blocker, protects heart cells by improving mitochondrial function and reducing oxidative stress. Its antioxidant properties enhance cardiomyocyte resistance, benefiting patients with heart disease.

Area of Science:

  • Cardiology
  • Mitochondrial Biology
  • Pharmacology

Background:

  • Beta-blockers are crucial for ischemic heart disease management by reducing myocardial oxygen demand.
  • Intracellular mechanisms of beta-blockers vary, necessitating a deeper understanding of individual drug actions.
  • Carvedilol, a non-selective beta-blocker with alpha-blocking properties, is used for hypertension, heart failure, and coronary artery disease.

Purpose of the Study:

  • To investigate the effects of carvedilol on cardiac mitochondria.
  • To explore the relationship between carvedilol's antioxidant properties and improved cardiomyocyte resistance.
  • To elucidate carvedilol's role in preventing doxorubicin-induced cardiotoxicity and its overall impact on cardiac function.

Main Methods:

  • Analysis of carvedilol's impact on mitochondrial parameters: oxidative phosphorylation, calcium homeostasis, and energy production.
  • Examination of carvedilol's role in modulating the mitochondrial permeability transition (MPT) and mitigating oxidative stress.
  • Evaluation of carvedilol as an enzyme modulator, particularly in preventing doxorubicin cardiotoxicity.

Main Results:

  • Carvedilol influences mitochondrial oxidative phosphorylation, calcium handling, and energy production.
  • Its antioxidant properties effectively minimize oxidative stress, a key inducer of MPT.
  • Carvedilol demonstrates enzyme-modulating effects beneficial in preventing doxorubicin cardiotoxicity.

Conclusions:

  • Carvedilol exhibits unique molecular mechanisms distinct from other beta-blockers.
  • Its mitochondrial-related cardioprotective effects contribute to improved cardiac function and patient prognosis.
  • Carvedilol's multifaceted actions underscore its significance in managing heart disease.

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...